Editas Medicine (EDIT) Earnings Date, Estimates & Call Transcripts → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free EDIT Stock Alerts $5.22 -0.13 (-2.43%) (As of 04/25/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Earnings SummaryUpcoming Earnings DateMay. 3EstimatedActual EPS (Feb. 28) -$0.23 Beat By $0.29 Consensus EPS (Feb. 28) -$0.52 Read Call TranscriptListen to Call Get Editas Medicine Earnings AlertsEnter your email address below to receive the latest news and earnings results for EDIT and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueEDIT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.EDIT Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. Editas Medicine Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($0.85)($0.44)($0.65)Q2 20242($0.86)($0.46)($0.66)Q3 20242($0.75)($0.46)($0.61)Q4 20242($0.79)($0.48)($0.64)FY 20248($3.25)($1.84)($2.55)Q1 20251($0.81)($0.81)($0.81)Q2 20251($0.77)($0.77)($0.77)Q3 20251($0.75)($0.75)($0.75)Q4 20251($0.72)($0.72)($0.72)FY 20254($3.05)($3.05)($3.05)EDIT Earnings Date and InformationEditas Medicine last released its earnings data on February 28th, 2024. The reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.29. The company earned $60 million during the quarter, compared to analysts' expectations of $4.84 million. Its revenue was up 817.4% on a year-over-year basis. Editas Medicine has generated ($2.05) earnings per share over the last year (($2.05) diluted earnings per share). Earnings for Editas Medicine are expected to decrease in the coming year, from ($2.61) to ($2.70) per share. Editas Medicine has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, May 3rd, 2024 based off prior year's report dates.Read More Editas Medicine Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/3/2024Estimated)------- 2/28/2024Q4 2023($0.52)($0.23)+$0.29($0.23)$4.84 million$60.00 million 11/3/2023Q3 2023($0.64)($0.55)+$0.09($0.55)$3.70 million$5.34 million 8/2/2023Q2 2023($0.76)($0.56)+$0.20($0.56)$4.17 million$2.89 million 5/5/2023Q1 2023($0.79)($0.71)+$0.08($0.71)$3.29 million$9.90 million 2/22/2023Q4 2022($0.84)($0.88)($0.04)($0.88)$3.76 million$6.54 million 11/2/2022Q3 2022($0.87)($0.81)+$0.06($0.81)$5.86 million$0.04 million Get the Latest News and Ratings for EDIT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. 8/3/2022Q2 2022($0.84)($0.78)+$0.06($0.78)$4.29 million$6.36 million 5/4/2022Q1 2022($0.81)($0.74)+$0.07($0.74)$3.85 million$6.80 million 2/24/2022Q4 2021($0.78)($0.61)+$0.17($0.61)$4.70 million$12.50 million 11/8/2021Q3 2021($0.81)($0.57)+$0.24($0.57)$4.92 million$6.20 million 8/4/2021Q2 2021($0.85)($0.81)+$0.04($0.81)$6.78 million$0.38 million 5/5/2021Q1 2021($0.76)($0.86)($0.10)($0.86)$5.78 million$6.50 million Editas Medicine Earnings - Frequently Asked Questions When is Editas Medicine's earnings date? Editas Medicine has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, May 3rd, 2024 based off last year's report dates. Learn more on EDIT's earnings history. Did Editas Medicine beat their earnings estimates last quarter? In the previous quarter, Editas Medicine (NASDAQ:EDIT) reported ($0.23) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.52) by $0.29. Learn more on analysts' earnings estimate vs. EDIT's actual earnings. How can I listen to Editas Medicine's earnings conference call? The conference call for Editas Medicine's latest earnings report can be listened to online. Listen to Conference Call How can I read Editas Medicine's conference call transcript? The conference call transcript for Editas Medicine's latest earnings report can be read online. Read Transcript How much revenue does Editas Medicine generate each year? Editas Medicine (NASDAQ:EDIT) has a recorded annual revenue of $78.12 million. How much profit does Editas Medicine generate each year? Editas Medicine (NASDAQ:EDIT) has a recorded net income of -$153.22 million. EDIT has generated -$2.05 earnings per share over the last four quarters. What is Editas Medicine's EPS forecast for next year? Editas Medicine's earnings are expected to decrease from ($2.61) per share to ($2.70) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Taysha Gene Therapies Earnings Results C4 Therapeutics Earnings Results Tourmaline Bio Earnings Results Alector Earnings Results Exscientia Earnings Results Replimune Group Earnings Results Voyager Therapeutics Earnings Results Fate Therapeutics Earnings Results Mesoblast Earnings Results Ocugen Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:EDIT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
